重组人血管内皮抑制素联合化疗治疗多种晚期恶性肿瘤

Recombinant human endostatin combined with chemotherapy in treatment of advanced malignant tumors

目的:观察抗肿瘤新药重组人血管内皮抑制素注射液(恩度)联合化疗治疗多种晚期恶性肿瘤的有效性和安全性。方法:经组织学或细胞学确诊的恶性肿瘤患者29例(包括消化系统肿瘤18例,非小细胞肺癌8例,其他肿瘤3例)接受恩度加常规化疗药物联合治疗,恩度剂量为7.5mg/m2,加入生理盐水500ml中缓慢静脉滴注3～4小时,滴注过程中给予心电监护,第1～14天连续给药,同时给予既往未使用的或与既往治疗无交叉耐药的化疗药物,每3周重复。按照RECIST标准评价近期客观疗效,按照NCI CTC 3.0版的分级标准评价药物毒性。治疗1周期后评价毒性,2周期后评价疗效。结果:29例患者中28例可评价疗效,获PR 9例,SD 12例,PD 7例,临床有效率为32.1%(9/28),临床受益率为75.0%(21/28),未出现严重毒副反应。结论:恩度联合化疗治疗多种晚期恶性肿瘤近期疗效较好,毒副反应可以耐受。

Objective：To evaluate the efficacy and safety with the combination of rb-endostatin （endostar） and chemotherapy in patients with advanced malignant tumors. Methods ： Twenty-nine patients with advanced cancers confirmed by histopathology or eytopathology were administrated with endostar 7.5mg,/m2 （day 1-14） by vein infusion of 3-4 hours and routine chemotherapy every 3 weeks. The overall response and toxicity were observed. Results：Twenty-nine patients were entered, 28 patients were evaluable. Par- tial response was observed in 9 patients,stable disease in 12 patients and progressive disease in 7 patients. Overall response rate was 32. 1% （9/28）, clinical benefit rate was 75% （21/28）. No serious adverse events were observed. Conclusion：The rh-endostatin combined with chemotherapy tends to show a better efficacy than chemotherapy alone and is well tolerated in advanced malignant tumors patients. No obviously adverse event was observed in these patients.